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For G-protein-coupled receptors (GPCRs) in general, the
roles of extracellular residues are not well defined compared
with residues in transmembrane helices (TMs). Nevertheless,
extracellular residues are important for various functions in
both peptide-GPCRs and amine-GPCRs. In this study, the V1a
vasopressin receptor was used to systematically investigate
the role of extracellular charged residues that are highly con-
served throughout a subfamily of peptide-GPCRs, using a
combination of mutagenesis and molecular modeling. Of the
13 conserved charged residues identified in the extracellular
loops (ECLs), Arg116 (ECL1), Arg125 (top of TMIII), and
Asp204 (ECL2) are important for agonist binding and/or
receptor activation. Molecular modeling revealed that Arg125
(and Lys125) stabilizes TMIII by interacting with lipid head
groups. Charge reversal (Asp125) caused re-ordering of the
lipids, altered helical packing, and increased solvent penetra-
tion of the TM bundle. Interestingly, a negative charge is
excluded at this locus in peptide-GPCRs, whereas a positive
charge is excluded in amine-GPCRs. This contrasting con-
served chargemay reflect differences in GPCR bindingmodes
between peptides and amines, with amines needing to access
a binding site crevice within the receptor TMbundle, whereas
the binding site of peptide-GPCRs includes more extracellu-
lar domains. A conserved negative charge at residue 204
(ECL2), juxtaposed to the highly conserved disulfide bond,
was essential for agonist binding and signaling. Asp204 (and
Glu204) establishes TMIII contacts required for maintaining
the -hairpin fold of ECL2, which if broken (Ala204 or Arg204)
resulted in ECL2 unfolding and receptor dysfunction. This
study providesmechanistic insight into the roles of conserved
extracellular residues.
G-protein-coupled receptors (GPCRs)4 exhibit a common
tertiary structure comprising seven transmembrane helices
(TMs) linked by extracellular loops (ECLs) and intracellular
loops. The atomic detail of this general GPCR fold has been
elucidated for bovine rhodopsin (bRho) using x-ray crystallog-
raphy (1). This confirmed that the chromophore 11-cis-retinal
is covalently linked to Lys296(7.43) in transmembrane helix VII
(TMVII) via a protonated Schiff-base and projects into a bind-
ing pocket formedwithin theTMbundlewhere it interactswith
amino acid side chains and water molecules (1, 2).5 Likewise,
the binding pocket for small biogenic amine neurotransmitters
such as acetylcholine and norepinephrine is buried deep within
the TM bundle (3). Nevertheless, it is known from the bRho
x-ray structure that the extracellular domains possess defined
structure and are orientated to interact with each other and
with the TM helices. Indeed ECL2 of bRho forms a -hairpin
that plunges down into the helical bundle to form a plug over
the chromophore. Furthermore, the orientation of ECL2 in the
majority of GPCRs is restrained by a conserved disulfide bond
between ECL2 and the top of TMIII (1, 2).
The neurohypophysial peptide hormones vasopressin (AVP)
and oxytocin (OT) generate a wide range of physiological
effects, including vasopressor and antidiuretic and uterotonic
actions (4, 5). The effects of AVP/OT are mediated by a family
of receptors (V1aR, V1bR, V2R, and OTR), which together with
the vasotocin receptor (VTR),mesotocin receptor, and isotocin
receptor from lower vertebrates constitute a subfamily of the
rhodopsin/-adrenergic receptor class of GPCRs (family A).
The V1aR, V1bR, and OTR couple to phospholipase C thereby
generating inositol 1,4,5-trisphosphate and diacylglycerol as
second messengers, whereas the V2R stimulates adenylyl
cyclase. The V1aR is widely distributed and mediates nearly all
of the actions of AVP with the exceptions of antidiuresis (V2R)
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and ACTH secretion (V1bR). Activation of the OTR stimulates
contraction of the uterine myometrium during labor and
causes lactation. In addition to the characteristic architecture
of GPCRs, members of the neurohypophysial peptide hormone
receptor family share certain sequence motifs and exhibit
related pharmacologies (5–7). The hormone-binding site of
these receptors includes residues in the TM bundle (8) and
ECL1 (9–11). It has also been reported that theN termini of the
V1aR and OTR are required for agonist binding (12, 13). In
particular, two charged residues (Arg46 and Glu54) in the V1aR
N terminus are required for high affinity agonist binding but
not antagonist binding (14, 15). Likewise, Arg34 in the N termi-
nus of the OTR is required for agonist binding (16).
For GPCRs in general, the roles of extracellular residues are
not well understood compared with residues in the TM
domain. Nevertheless, extracellular residues are important for
binding both amine (17) and peptide (18) ligands and have been
implicated in ligand receptor-subtype specificity (19), binding
allosteric modulators (20), switching ligand agonist/antagonist
properties (21), and human immunodeficiency virus co-recep-
tor activity (22). The aim of this study was to use the V1aR to
systematically investigate the function of extracellular charged
residues that are highly conserved throughout a subfamily of
peptide GPCRs. By using a combination of mutagenesis and
molecular modeling, our results indicate that specific con-
served charged residues in ECL1, ECL2, and ECL3 fulfill impor-
tant roles in ligand binding, receptor activation, domain con-
formation, and cell-surface expression.
EXPERIMENTAL PROCEDURES
Materials—AVP was purchased from Sigma. The cyclic peptide
antagonist (CA) 1-(-mercapto-,-cyclopentamethylenepropionic
acid), 2-(O-methyl)tyrosine AVP (d(CH2)5Tyr(Me)2AVP), and
linear peptide antagonist (LA) phenylacetyl (PhAc)-D-
Tyr(Me)2Arg6Tyr(NH2)9AVP were from Bachem (St. Helens,
UK). SR 49059 was a gift from Sanofi Recherche (Toulouse,
France). Cell culturemedia, buffers, and supplementswere pur-
chased from Invitrogen. Restriction enzymes were obtained
fromMBI Fermentas (Sunderland, UK).
Mutant Receptor Constructs—Mutation of the V1aR was
made using a PCR approach as described previously (15). The
mutant receptor constructs [D112A]V1aR, [R116A]V1aR,
[R118A]V1aR, [D121A]V1aR, and [R125A]V1aR were engineered
using the antisense oligonucleotides as follows: 5-GGC-AAA-C-
AC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-
GTC-GGG-CCC-GCG-GAA-GCG-GTA-GGT-GAT-GGC-C-
CA-GC-3; 5-GGC-AAA-CACCTG-CAG-GTG-CTT-CAC-C-
AC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GCG-GAA-GG-
C-GTA-GG-3; 5-GGC-AAA-CAC-CTG-CAG-GTG-CTT-C-
AC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GGC-GA-
A-GCG-G-3; 5-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CA-
C-CAC-GCG-GCA-CAG-CCA-GGC-GGG-CCC-3; and 5-G-
GC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GGC-G-
CA-CAG-CCA-GTC-GGG-CCC-3, respectively. Each primer
contained a unique SdaI restriction site (underlined) and base
changes (shown in boldface) to generate each individual Ala
substitution plus base changes to create a silentApaI restriction
site for diagnostic purposes (shown in italics). The same cloning
strategy was employed to generate the mutant constructs
[D112E]V1aR, [D112K]V1aR, [D112R]V1aR, [R116D]V1aR,
[R116E]V1aR, [R116K]V1aR, [R125D]V1aR, and [R125K]V1aR
using the antisense oligonucleotides as follows: 5-GGC-AAA-
CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-C-
CA-GTC-GGG-CCC-GCG-GAA-GCG-GTA-GGT-GAT-C-
TC-CCA-GC-3; 5-GGC-AAA-CAC-CTG-CAG-GTG-CTT-
CAC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GCG-
GAA-GCG-GTA-GGT-GAT-TTT-CCA-GC-3; 5-GGC-
AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-C-
AG-CCA-GTC-GGG-CCC-GCG-GAA-GCG-GTA-GGT-G-
AT-GCG-CCA-GC-3; 5-GGC-AAA-CAC-CTG-CAG-
GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-C-
CC-GCG-GAA-GTC-GTA-GGT-G-3; 5-GGC-AAA-CAC-
CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-
GTC-GGG-CCC-GCG-GAA-CTC-GTA-GGT-G-3; 5-GG-
C-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-
CAG-CCA-GTC-GGG-CCC-GCG-GAA-TTT-GTA-GGT-
G-3; 5-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-
GTC-GCA-CAG-CCA-GTC-GGG-CCC-3; and 5-GGC-AA-
A-CAC-CTG-CAG- GTG-CTT-CAC-CAC-TTT-GCA-CA-
G-CCA-GTC-GGG-CCC-3, respectively. PCR products were
subcloned into the HA epitope-tagged rat V1aR coding
sequence in the mammalian expression vector pcDNA3.1
(Invitrogen) utilizing unique HindIII and SdaI restriction sites.
The mutations [E193A]V1aR, [E195A]V1aR, [K201A]V1aR, and
[D204A]V1aR were made using antisense oligonucleotides as fol-
lows: 5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-GAA-
GGT-AGC-CCA-GCA-GTC-TTG-GGT-TTT-AGT-GCC-AT-
T-GTT-CAC-CTC-GAT-TGC-GAT-CAC-AGA-G-3; 5-GG-
C-GCG-GGT-ACC-CCA-GGG-CTG-GAT-GAA-GGT-AGC-
CCA-GCA-GTC-TTG-GGT-TTT-AGT-GCC-ATT-GTT-CA-
C-CGC-GAT-TTC-G-3; 5-GGC-GCG-GGT-ACC-CCA-
GGG-CTG-GAT-GAA-CGT-TGC-CCA-GCA-GTC-TTG-G-
GT-TGC-AGT-GCC-ATT-G-3; and 5-GGC-GCG-GGT-AC-
C-CCA-GGG-CTG-GAT-GAA-GGT-AGC-CCA-GCA-GGC-
TTG-GGT-TTT-AGT-GC-3, respectively. These primers con-
tained thebase changes (shown inboldface) to incorporate theAla
mutations and unique KpnI restriction site (underlined) used for
subcloning. The [D204E]V1aR and [D204R]V1aR mutations were
also engineered using this strategy using antisense oligonucleo-
tides as follows: 5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-G-
AT-GAA-GGT-AGC-CCA-GCA-CTC-TTG-GGT-TTT-AGT-
GC-3 and 5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-
GAA-GGT-AGC-CCA-GCA-GCG-TTG-GGT-TTT-AGT-G-
C-3. The construct [R216A]V1aR was made using sense
oligonucleotide 5-G-CCC-TGG-GGT- ACC-GCC-GCG-TAC-
GTG-ACC-TGG-ATG-ACC-TCA-GGT-GTC-TTC-GTG-G-
3. This primer contained five base changes in the V1aR sequence
(shown in boldface) that created the Ala mutation (shown in ital-
ics) unique silent Pfl23II and Eco81I restriction sites (for diagnos-
tic purposes) and a KpnI restriction site (underlined) for subclon-
ing into the V1aR.
The [E332A]V1aR mutation was made by PCR using both
sense and antisense oligonucleotides. The sense primer was 5-
C-GAT-TCA-GCA-AAC-CCA-TCGATA-ACA-ATC-ACG-
GCG-3. This primer contained four base changes in the V1aR
sequence (indicated in boldface) that created a unique func-
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tional ClaI restriction site (underlined) without altering the
amino acid sequence and incorporated the Glu3323Alamuta-
tion (shown in italics). A KpnI/EcoRI digest of this PCR frag-
ment was subcloned into the V1aR. The constructs
[D323A]V1aR and [D330A]V1aR were made by PCR with
pcDNA3-[E332A]V1aR as template. Mutant antisense oligonu-
cleotides were 5-CGT-GAT-TGT-TAT-CGA-TGG-GTT-T-
TC-TGA-ATC-GGT-CCA-GAT-GAA-ATT-CTC-AGC-CC-
A-GAC-TGA-CC-3 and 5-CGT-GAT-TGT-TAT-CGA-TG-
G-GTT-TTC-TGA-AGC-GGT-CCA-GAT-GAA-ATT-CTC-
ATC-C-3 for [D323A]V1aR and [D330A]V1aR mutations,
respectively. These primers contained base changes (shown in
boldface) for the required Ala substitution and unique ClaI
restriction site (underlined). The PCRproductswere subcloned
into pcDNA3-[E332A]V1aR utilizing unique SdaI and ClaI
restriction sites. All receptor constructs were confirmed by
automated fluorescent sequencing (University of Birmingham,
Birmingham, UK).
Cell Culture and Transfection—HEK 293T cells were rou-
tinely cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% (v/v) fetal calf serum in humidified 5%
(v/v) CO2 in air at 37 °C. Cells were seeded at a density of
5 105 cells/100-mm dish and transfected after 48 h using
a calcium phosphate precipitation protocol with 10 g of
DNA/dish (16).
Radioligand Binding Assays—A washed cell membrane prep-
aration ofHEK293Tcells, transfectedwith the appropriate recep-
tor construct, was prepared as described previously (23), and the
protein concentration was determined using the BCA protein
assay kit (Pierce) using bovine serum albumin as standard. Radio-
ligand binding assayswere performed as described previously (24)
using either the natural agonist [Phe3-3,4,5-3H]AVP (0.5–1.5 nM),
(64.2 Ci/mmol; PerkinElmer Life Sciences) or the V1aR-selective
peptide antagonist [Phe3-3,4,5-3H]d(CH2)5Tyr(Me)2AVP (0.5–
1.5 nM) (99 Ci/mmol; PerkinElmer Life Sciences) (25) as tracer
ligand.Binding datawere analyzed by nonlinear regression to fit
theoretical Langmuir binding isotherms to the experimental
data using PRISM Graphpad (Graphpad Software Inc., San
Diego). Individual IC50 values obtained for competing ligands
were corrected for radioligand occupancy as described (26)
using the radioligand affinity (Kd) experimentally determined
for each construct.
Whole Cell Vasopressin V1a Receptor Binding —HEK 293T
cells were plated onto 12-well plates at a density of 2.5 105 cells/
well in poly-D-lysine-coated 12-well plates and transfected after
24husingTransfastTM (PromegaCorp., Southampton,UK).After
36 h, eachwell received 0.5ml of binding buffer (described above)
containing 2% (w/v) BSA, 1–2 nM V1aR-selective peptide antago-
nist PhAc-D-Tyr(Me)2Arg6(3,4[3H]Pro)(3,5[3H]Tyr)9NH2-AVP
(22 Ci/mmol; custom synthesis Phoenix Pharmaceuticals, INC.
Belmont, CA) as tracer ligand in the presence (nonspecific) or
absence (total) of 1 M LA. Plates were incubated for 90 min at
37 °C, before removal of the medium by aspiration. After three
rinses with ice-cold phosphate-buffered saline, 0.5 ml of 0.1 M
NaOHwasaddedtoeachwell toextract radioactivity.After15min
of incubation at 37 °C, the fluid from the plates was transferred to
scintillation vials containing 10 ml of HiSafe3 scintillant mixture
for counting. Cell-surface expression values were corrected for
radioligand occupancy as described (26) using the radioligand
affinity (Kd) experimentally determined for each construct.
Determination of Cell-surface Expression Using Enzyme-
linked Immunosorbent Assay —All receptor constructs incor-
porated an HA epitope tag in the N terminus that enabled cell
surface expression to be determined by enzyme-linked immu-
nosorbent assay (27). Briefly, HEK 293T cells were seeded at a
density of 1  105 cells/well in poly-D-lysine-coated 12-well
plates and transfected after 24 h using TransfastTM (Promega
Corp., Southampton,UK). After 36 h, cells were fixedwith 3.7%
(v/v) formaldehyde in TBS (20 mM Tris, pH 7.5, 150 mM
NaCl) for 15 min at 37 °C and then washed three times with
TBS. Nonspecific binding was blocked with 1% (w/v) BSA in
TBS for 45 min. Anti-HA primary antibody (HA-7; Sigma)
was diluted to 1:1000 in TBS containing 1% (w/v) BSA for 60
min at room temperature with occasional shaking, followed
by three gentle washes with TBS. Cells were briefly
re-blocked with 1% (w/v) BSA in TBS for 15 min, prior to
incubation with secondary antibody (alkaline phosphatase-
conjugated goat anti-mouse; Bio-Rad), and diluted to 1:3000
in 1% (w/v) BSA/TBS for 60 min with occasional shaking.
Cells were washed three times with TBS before a colorimet-
ric alkaline phosphate substrate (Bio-Rad) was added and
incubated at 37 °C for 30 min. A 100-l aliquot from each
well was mixed with an equal volume of 0.4 M NaOH prior to
measuring absorbance at 405 nm. Results were normalized
against a wild-type control processed in parallel. Nontrans-
fected cells were used to determine background. All experi-
ments were performed in quadruplicate.
AVP-induced Inositol Phosphates Production—HEK 293T
cells were seeded at a density of 2.5 105 cells/well in poly-D-
lysine-coated 12-well plates and transfected after 24 h using
TransfastTM (Promega). AVP-induced accumulation of inositol
phosphates (InsPs) was assayed as described previously (12).
Briefly, following pre-labeling of transfected cells with 2Ci/ml
myo-[2-3H]inositol (22.0 Ci/mmol; PerkinElmer Life Sciences)
in inositol-free Dulbecco’s modified Eagle’s medium contain-
ing 1% (v/v) fetal calf serum, a mixed fraction containing
mono-, bis-, and trisphosphates (InsP-InsP3) was collected fol-
lowing stimulation by AVP, at the concentrations indicated, in
the presence of 10 mM LiCl.
Molecular Modeling of the V1aR—The V1aR sequence was
aligned against the sequence corresponding to the crystal struc-
ture coordinates of bRho using ClustalW (28). The alignment
was then used to generate homologymodels usingMODELLER
version 6.2 (29). A collection of 200 model structures was gen-
erated and ranked based on an objective function score pro-
vided by MODELLER version 6.2. From this ensemble, a single
structure was selected for further analysis. Further refinement of
the homology model was achieved through molecular dynamics
(MD) simulations of the receptor embedded in a hydrated 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine bilayer. MD simula-
tions were carried out using the GROMOS96 force-field parame-
ters, with minor modifications, as implemented in GROMACS
(30). Partial charges for theheavy atomsof Lys andArg side chains
were determined using the 6-31G basis set as implemented in
GAMESS US.
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RESULTS
Role of Charged Residues in the First Extracellular Loop
(ECL1) of the V1aR—The sequences of the extracellular loops,
plus the extracellular boundaries, of the neurohypophysial pep-
tide hormone subfamily of GPCRs are aligned in Fig. 1A.
Within ECL1 (including the extracellular regions of TMII and
TMIII), there are five conserved charged residues as follows:
Asp112, Arg116, Arg118, Asp121, and Arg125 (Fig. 1B, residue
number is based on rV1aR). Residues Arg116, Asp121, andArg125
are absolutely conserved across all VPR/OTRs cloned to date
(Fig. 1A). Asp112 is also conserved with the exception of the
human V2R (Lys) and the VTR (Glu). Arg118 is only conserved
FIGURE 1. The extracellular face of neurohypophysial hormone receptors. A, sequence alignment of the extracellular loop regions of vasopressin and
oxytocin receptors cloned from different species. The sequences of the extracellular loop regions (ECL1, ECL2, and ECL3) of the V1aR, OTR, V1bR, and V2R from
different species have been aligned. The species of origin is indicated by a single letter code preceding the receptor subtype: r, rat;m, mouse; v, vole; s, sheep;
h, human; p, pig; b, cow;mky, rhesus monkey; d, dog. Also shown is the sequence of the vasotocin and isotocin receptors from teleost fish and an amphibian
mesotocin receptor. Conserved charged residues within these domains that were investigated in this study are boxed and numbered according to the rV1aR
sequence. Sequences cited were obtained from Swiss Protein Database and GenEMBL. B, schematic diagram of the extracellular face of the rV1aR. Residues
shown aswhite text on a black circle are the conserved charged residues investigated in this study.
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in V1aRs, although positively charged residues are present at
this locus in all V2Rs (Fig. 1A).
To assess the importance of these conserved residues inV1aR
function, each residue was substituted individually by Ala and
then pharmacologically characterized using the natural agonist
AVP and three different structural classes of antagonist as fol-
lows: (i) CA, [d(CH2)5Tyr(Me)2]AVP (25); (ii) LA ([PhAc-D-
Tyr(Me)2Arg6Tyr(NH2)9]AVP (31)); and (iii) nonpeptide
antagonist (SR 49059; (32)). The Kd values are presented in
Table 1, corrected for radioligand occupancy.Mutating Arg116,
Arg118, Asp121, or Arg125 to Ala had only a slight effect on the
binding of the agonist AVP or the three different classes of
antagonist (Table 1 and Fig. 2). [D112A]V1aR was also essen-
tially wild type, although the Kd value for LA was slightly
(5-fold) increased. Furthermore, the mutations [D112A]V1aR,
[R118A]V1aR, and [D121A]V1aR had little effect on signaling,
with EC50 values for AVP-stimulated inositol phosphate (InsP-
InsP3) accumulations comparable with wild-type V1aR (Table
1). In contrast, [R116A]V1aR and [R125A]V1aR had a marked
effect on signaling, increasing the EC50 value 70- and 16-fold,
respectively, compared with the wild type (Fig. 3, A and B).
A Positive Charge Is Required at Residue 116 in ECL1—The
charge requirements of residue 116 were investigated further
by engineering [R116D]V1aR, [R116E]V1aR (incorporating a
negative charge), and [R116K]V1aR (maintaining a positive
charge). A negative charge was not tolerated at this position, as
the affinity of AVP decreased 1600- and 730-fold for
[R116D]V1aR and [R116E]V1aR, respectively, compared with
wild-type V1aR (Fig. 2A). In contrast, the binding affinities of
the three different antagonists to [R116D]V1aR and
[R116E]V1aR were relatively unchanged, although a small
decrease (6-fold) was observed for CA (Table 1). Incorporat-
ing a negative charge at this locus also perturbed receptor acti-
vation, increasing the EC50 value for [R116D]V1aR and
[R116E]V1aR by 53- and 23-fold, respectively (Fig. 3A). In con-
trast, maintaining a positive charge at this position
([R116K]V1aR) resulted in a receptor that exhibited essentially
wild-type binding (Fig. 2A and Table 1) and signaling (Fig. 3A).
A Positive Charge Is Required at Residue 125 in ECL1—The
charge requirements of residue 125 were investigated further.
Retaining a positive charge ([R125K]V1aR) resulted in a wild-
type receptor profile (Table 1). In contrast, introduction of a
negative charge at this locus ([R125D]V1aR) ablated specific
binding of the radio-tracers (agonist and antagonist) and
impaired signaling, with a marked decrease in AVP potency
comparedwithwild-typeV1aR (Fig. 3B).Molecularmodeling of
the V1aR indicated that Arg125 orientates into the lipid bilayer
(Fig. 4A), with the side-chain methylene groups interacting
with the lipid hydrocarbon tails and the guanidinium group
interacting with the lipid phosphate head groups and solvent.
These contacts are preserved in [R125K]V1aR, consistent with
the wild-type characteristics of this mutant receptor. In con-
trast, molecular dynamics of [R125D]V1aR revealed a re-order-
ing of the phospholipids in this region resulting from mutual
repulsion between the negatively charged lipid phosphate head
group and the carboxyl of the Asp side chain. This re-ordering
of the lipids increased solvent accessibility at the extracellular
end of TMIII and TMIV (Fig. 4A).
Species-specific and Receptor Subtype-specific Differences at
Position 112 in ECL1—An Asp is highly conserved at residue
112 throughout this family of GPCRs, with the exception of
the VTR and the human V2R that possess Glu and Lys,
respectively (Fig. 1). Pharmacological differences arising
from this sequence variation were assessed. Conservative sub-
stitution ([D112E]V1aR) resulted in wild-type binding and
intracellular signaling, with only a small change in affinity for
the CA antagonist (3-fold). Reversing the charge in
[D112K]V1aR also slightly decreased the affinity of CA (5-fold)
and reduced the affinity of the linear antagonist LA 8-fold
(Table 1) but was otherwise wild type (Fig. 3C). However, in
marked contrast to [D112K]V1aR, the construct [D112R]V1aR
exhibited low affinity for AVP (Fig. 2B) and perturbed signaling
(Fig. 3C). These effects were not because of a nonspecific dis-
ruption of the receptor tertiary fold as the affinity of the three
classes of antagonist was unchanged (Table 1).
Asp112 is located at the membrane/solvent interface at the
extracellular end of TMII. Molecular modeling shows that
when residue 112 isGlu or Lys, they occupy a similar position to
Asp112, consistentwith the nearwild-type profile observedwith
these constructs. However, the increased side-chain length of
Arg112 compared with Lys112 positions the positively charged
guanidiniummoiety of Arg112 3.0 Å from the carboxyl group of
Glu54(1.35) (top of TMI), resulting in a charge-charge interac-
tion between these two residues (Fig. 4B). A comparable inter-
action between the amine of Lys112 and Glu54 is far less likely as
the functional groups are further apart (4.8 Å). Furthermore,
the guanidinium of Arg has higher partial charges on its heavy
atoms compared with the amine of Lys, which increases the
potential of the Arg guanidinium to establish ionic interactions
compared with the amine of Lys. In addition, the planar nature
of the guanidinium group may aid directive interactions.
Role of Charged Residues in the 2nd Extracellular Loop
(ECL2) of the V1aR—The ECL2 domain (including the extracel-
lular borders of TMIV and TMV) of the V1aR contains five
charged residuesGlu193, Glu195, Lys201, Asp204, andArg216 (Fig.
1B). Sequence analysis of ECL2 revealed the following: (i)
charged residues are well conserved at loci corresponding to
Glu195, Asp204, and Arg216 throughout the vertebrate VPR/
OTR family, whereas Glu193 and Lys201 are found only in the
V1aR subtype; (ii) Asp204 is absolutely conserved with the sin-
gle exception of the chick VTR, which has a Glu (33); (iii) a
negative charge (usually aGlu but anAsp inV2Rs) is conserved
at residue 195 with the exception of the human V2R, which has
Asn; and (iv) a positive charge (Arg/Lys) is conserved at posi-
tion 216 but is replaced by a Pro in the sheep V1aR (Fig. 1A).
To assess the functional importance of these conserved
charged residues, each residue wasmutated individually to Ala,
and the pharmacological characteristics were compared with
wild-type V1aR (Table 1). With the exception of [D204A]V1aR,
all the mutant constructs exhibited binding and signaling char-
acteristics similar to wild type (Table 1). In marked contrast,
[D204A]V1aR possessed a marked decrease in AVP affinity
(2300-fold; Fig. 2C and Table 1) and impaired signaling (Fig.
3D). The affinity of [D204A]V1aR for the cyclic and nonpeptide
antagonists remained unchanged (Table 1), indicating that the
receptor protein was folded appropriately; nevertheless, the Kd
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TABLE 1
Pharmacological profile of mutant V1aRs
Mutant V1aRs were expressed in HEK 293T cells and characterized pharmacologically. Dissociation constants (Kd) were calculated from IC50 values and corrected for
radioligand occupancy as described under “Experimental Procedures.”Data shown are themean S.E. (n 3) of three replicates. SR 49059 indicates nonpeptide antagonist.
EC50 and Emax values of AVP-induced accumulation of InsP-InsP3 in cells expressing wild-type (WT) and mutant receptors are shown. Values shown are the mean S.E.
of three separate experiments performed in triplicate. NS indicates no stimulation. *, data were taken fromRef. 34. Basal values (mean S.E.) were 1217 252, 1263 224,
1135 201, 1080 158, 1214 207, 1073 223, 984 198, 956 214, 1075 248, 1256 258, 1208 174, 1007 125, 1283 202, 1321 230, 1299 188, 1116
207, 1302  191, 1350  260, 956  239, 1150  176, 1045  115, 1263  239, 1371  206, 1298  117, 1228  223, 1008  182, and 1251  248 dpm for wild type,
[D112A]V1aR, [D112E]V1aR, [D112K]V1aR, [D112R]V1aR, [D116A]V1aR, [D116D]V1aR, [D116E]V1aR, [D116K]V1aR, [R118A]V1aR, [D121A]V1aR, [R125A]V1aR,
[R125D]V1aR, [R125K]V1aR, [E193A]V1aR, [E195A]V1aR, [D204A]V1aR, [D204E]V1aR, [D204R]V1aR, [K201A]V1aR, [R216A]V1aR, [R46D]V1aR, [R46D/D204R]V1aR,
[R125D/D204R]V1aR, [D323A]V1aR, [D330A]V1aR, and [E332A]V1aR respectively. None of themutant receptors displayed constitutive activity. Cell-surface expressionwas
determined, mean S.E. (n 3), in parallel experiments as a percentage relative to wild-type V1aR using an ELISA-based assay, or as pmol/mg protein (Bmax) using whole
cell 3H-labeled LA binding where possible, as described under “Experimental Procedures.”
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value for LA was increased 20-fold relative to wild type (Table
1). The charge requirements at position 204 were investigated.
Retaining a negative charge ([D204E]V1aR) resulted in wild-
type ligand binding and signaling (Figs. 2C and 3D andTable 1),
whereas reversing the charge ([D204R]V1aR) markedly
decreased both AVP affinity (Fig. 2C) and signaling (Fig. 3D)
and to a lesser extent LAandCAaffinity (24- and 6-fold, respec-
tively; Table 1). The binding of the nonpeptide antagonist to
[D204R]V1aR was wild type.
Investigating a Possible Interaction between Asp204 and
Arg125 or Arg46—Mutagenesis of Asp204 or Arg125 gene-
rated similar effects. Consequently, substitution by Ala
([D204A]V1aR and [R125A]V1aR) decreased the potency of
AVP signaling by20-fold compared with wild-type V1aR (Fig.
3, D and B, respectively), and reversing the charge
([D204R]V1aR and [R125D]V1aR) increased the EC50 100-fold
comparedwith wild-type V1aR. AlthoughArg125 (top of TMIII)
and Asp204 (ECL2) are in different domains, they are located at
opposite ends of the highly conserved disulfide bond and there-
fore in close proximity and spatially constrained. It was possible
that amutual charge interaction existed between these two res-
idues, whichwas required for receptor activation. However, the
double-reciprocal mutant [R125D/D204R]V1aR did not bind
3H-labeled tracer ligands, did not signal when challenged with
AVP (10 M), and was poorly expressed (Table 1). Conse-
quently, these data do not support a mutual interaction
between Arg125 and Asp204.
We have established previously that a single residue (Arg46)
located within the distal N terminus of the V1aR is critical for
binding AVP but not peptide or nonpeptide antagonists (14)
and that reversing the charge at this locus ([R46D]V1aR or
[R46E]V1aR) impaired receptor function (34) in a similar man-
ner to that observed for [D204R]V1aR in this study. Given that
high affinity agonist binding required both Arg46 and Asp204, it
was feasible that a direct intra-molecular ionic interaction
between Arg46 and Asp204 may contribute to high affinity ago-
nist binding and receptor activation. However, the double-re-
ciprocal mutant [R46D/D204R]V1aR bound AVP with very low
affinity (Kd  2500 nM), a similar affinity to [R46D]V1aR or
[D204R]V1aR (Table 1), and the signaling capability of [R46D/
D204R]V1aR was also severely compromised. The overall terti-
ary fold of the receptor was nevertheless good as the nonpep-
tide antagonist bound with wild-type affinity, and the peptide
antagonists CA and LA also bound with high affinity, albeit less
than wild type (Table 1). Cell-surface expression of [R46D/
D204R]V1aR was only 20% of wild type. These data do not
provide evidence for a direct interaction between Arg46 and
Asp204.
Molecular modeling indicated that Asp204 lies at the center
of a pocket defined by residues Lys128(3.29) (TMIII), Gln131(3.32)
(TMIII), Trp206 (ECL2), Phe283(6.51) (TMVI), and Gln287(6.55)
(TMVI). Asp204 forms a salt bridge with Lys128(3.29) and hydro-
gen bonds with Gln131(3.32), both in TMIII (Fig. 4C). These
interactions with Lys128(3.29) and Gln131(3.32) are preserved in
the conservative substitution [D204E]V1aR (not shown), con-
sistent with the wild-type pharmacological profile (Table 1).
Removal of the negative charge at this locus ([D204A]V1aR)
resulted in a decrease in both AVP affinity and signaling
potency (Fig. 3D and Table 1). MD simulation of [D204A]V1aR
revealed that removal of the negative charge breaks the wild-
type contacts between ECL2 and TMIII (Fig. 4D). This leads to
a partial unfolding of the -hairpin within ECL2 (Fig. 4E). In
addition, the side chain of Lys128 rotates away from itswild-type
position and orientates toward TMVI (Fig. 4D). A similar per-
FIGURE 2. Pharmacological characterization of ECL mutant receptors.
Radioligand binding studies with AVP as competing ligand were performed
using a membrane preparation of HEK 293T cells transiently transfected as
follows. A, wild-type (Arg116) V1aR (E); [R116A]V1aR (F); [R116E]V1aR ();
[R116D]V1aR (Œ); and [R116K]V1aR (). B, wild-type (Asp
112) V1aR (E);
[D112A]V1aR (F); [D112E]V1aR (); [D112K]V1aR (); and [D112R]V1aR (f).
C, wild-type (Asp204) V1aR (E); [D204A]V1aR (F); [D204E]V1aR (); and
[D204R]V1aR (f). Data are themeanS.E. of three separate experiments each
performed in triplicate using [3H]AVP (0.5–1.5 nM) or 3H-labeled CA (0.5–1.5
nM) as tracer. Values are expressed as percent specific binding, where non-
specific binding was defined by d(CH2)5Tyr(Me)
2AVP (1 M). A theoretical
Langmuir binding isotherm has been fitted to the experimental data as
described under “Experimental Procedures.”
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turbation was observed with the construct [D204R]V1aR, again
leading to re-organization of ECL2. However, the introduction
of an Arg at residue 204 also created an alternative hydrogen
bonding network involving new interactions between Arg204
in ECL2 and residues in TMII (Gln104(2.57) and Gln108(2.61)) and
TMVII (Ala272(7.42) and Ser273(7.43)) (Fig. 4F).
Role of Charged Residues in ECL3 of the V1aR—ECL3 (includ-
ing the extracellular borders of TMVI and TMVII) of the V1aR
contains three conserved charged residues Asp323, Asp330, and
Glu332 (Fig. 1B). Analysis of sequence alignments of ECL3 of the
vertebrate VPR/OTR family revealed the following: (i) anAsp is
completely conserved at the locus corresponding to Asp323; (ii)
a negative charge (usually anAsp) is conserved at residue 330 in
V1aRs, V1bRs, and VTRs but is replaced by Pro in OTRs and
V2Rs; and (iii) a Glu is conserved at the locus corresponding to
Glu332 with the exception of V1bRs that possess a Thr (Fig. 1A).
To determine the functional importance of these residues, each
residue wasmutated individually to Ala. Pharmacological char-
acterization established that [D323A]V1aR, [D330A]V1aR, and
[E332A]V1aR were almost identical to wild-type V1aR with
respect to binding all four classes of ligand (Table 1) and intra-
cellular signaling (Table 1), indicating that the conserved
charged residues in ECL3had little or no role in these functions.
However, it was noteworthy that [D323A]V1aR exhibited
reduced cell-surface expression (50%) compared with wild-
type V1aR (Table 1).
DISCUSSION
The aim of this study was to use the V1aR to systematically
investigate the function of extracellular charged residues that
are highly conserved throughout a subfamily of peptideGPCRs.
Within the ECL domains of the
V1aR, the charged residues were
subdivided into the following two
groups: (i) those that are conserved
in all members of the subfamily, and
(ii) those that are conserved within a
specific subtype. Thirteen conserved
charged residues were identified in
the ECL domains and associated TM
boundaries, with five in ECL1, five in
ECL2, and three in ECL3. Ala sub-
stitution within ECL1 had little
effect on ligand binding. However,
[R116A]V1aR and [R125A]V1aR
exhibited impaired intracellular sig-
naling (70- and 16-fold, respec-
tively) indicating a role in receptor
activation. Although [R125A]V1aR
was expressed at 56% of wild type,
this was unlikely to be responsible
for the impaired signaling of
[R125A]V1aR, as [D323A]V1aR was
expressed at 52% of wild type but
retained essentially wild-type sig-
naling capability (Table 1). A posi-
tive charge is essential at residue
116, as retaining a positive charge
([R116K]V1aR) preservedwild-type signaling, and reversing the
charge ([R116D]V1aR and [R116E]V1aR) not only compromised
signaling but also profoundly decreased agonist affinity. This
loss of AVP binding was agonist-specific and not because of
aberrant assembly of the receptor as the binding of antagonists
(peptide and nonpeptide) was unaffected. Consequently,
Arg116 is required to stabilize the active R* conformation of the
V1aR and is absolutely conserved throughout the vertebrate
neurohypophysial hormone subfamily of GPCRs cloned to date
(Fig. 1A).
Arg125 is located close to the extracellular end of TMIII,
immediately adjacent to the conserved disulfide bond, where it
interacts with lipids. This Arg-lipid interaction has been
referred to as “snorkeling” (35). The absolute conservation of
this Arg throughout the neurohypophysial peptide hormone
receptor family (Fig. 1A) implies functional importance. This is
supported by a report that the naturally occurring mutation
R113W in the human V2R (which corresponds to Arg125 in the
V1aR) causes the receptor dysfunction responsible for nephro-
genic diabetes insipidus in some patients (36). Furthermore, an
alignment of 717 sequences of family A GPCRs, which bind
peptide ligands, revealed that a positively charged residue is
conserved at this position in 85% of receptors and that Asp and
Glu are excluded (see the GPCR data base). This is indicative of
a generic role for this residue in signaling by peptide-GPCRs, a
notion supported by mutagenesis studies on the CXCR2 and
angiotensin II type 1 receptors (37, 38). It is now well estab-
lished that relative movement between TMIII, TMVI, and
TMVII is central to the R3 R* transition of GPCRs (39). The
location of Arg125 at the extracellular extremity of TMIII may
allow it to act as a structural support for TMIII during receptor
FIGURE 3. Intracellular signaling by ECL mutant receptors. AVP-induced accumulation of mono-, bis-, and
trisphosphates in HEK 293T cells transiently transfected as follows. A, wild-type (Arg116) V1aR (E); [R116A]V1aR
(F); [R116E]V1aR (); [R116D]V1aR (Œ); and [R116K]V1aR (). B, wild-type (Arg
125) V1aR (E); [R125A]V1aR (F);
[R125D]V1aR (Œ); and [R125K]V1aR (). C, wild-type (Asp
112) V1aR (E); [D112A]V1aR (F); [D112E]V1aR ();
[D112K]V1aR (; and [D112R]V1aR (f). D, wild-type (Asp
204) V1aR (E); [D204A]V1aR (F); [D204E]V1aR (); and
[D204R]V1aR (f). Data are the mean S.E. of three separate experiments each performed in triplicate. Values
are stimulation induced by AVP at the stated concentrations expressed as percent maximum.
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activation. Reversing the charge at this locus in [R125D]V1aR
was very detrimental because of charge-charge repulsion
between the side-chain carboxyl and themembrane lipid phos-
phate head groups. This repulsion resulted in re-ordering of the
surrounding phospholipids, increased solvent accessibility at
the extracellular end of TMIII/TMIV, and altered local confor-
mation that could have ramifications along the length of TMIII.
These conformational changes observed in silicowould explain
why Asp/Glu are excluded from this locus in peptide-binding
GPCRs. In marked contrast, GPCRs for biogenic amines actu-
ally favor a negatively charged residue at the position corre-
sponding to Arg125. Analysis of an
alignment of 371 sequences of
amine-GPCRs from different spe-
cies revealed that 70% have Glu/
Asp at this locus (GPCR data base)
with the exclusion of Arg/Lys.
Exceptions to this trend are the H3
histamine receptor and trace amine
receptors that do possess a positive
charge. It is possible that the charge
difference at this single locus between
peptide-GPCRs and amine-GPCRs
may reflect differences in the bind-
ing mode between these ligands.
Biogenic amines access a binding
site enclosed within the TM bundle,
whereas peptides bind to extracellu-
lar domains plus TM helices. If Glu/
Asp at the top of TMIII in amine-
GPCRs (corresponding to Arg125 in
V1aR) increases solvent penetration
into the TM bundle (analogous to the
mutant [R125D]V1aR), it may facilitate
ligand access to the binding site. Sup-
port for such a mechanism is perhaps
provided by [3H]propylbenzylcholine
mustard ([3H]PrBCM) labeling of the
M1 mAChR. In addition to alkylat-
ing Asp105 in TMIII (the “classical”
amine counter-ion), [3H]PrBCM
also labeled Asp99 (corresponding
to Arg125 in the V1aR) (40). Further-
more, mutation of this Asp99 to Asn
moderately decreased the affinity of
a range of ligands and strongly
decreased both alkylation by
[3H]PrBCM and agonist-induced
second messenger generation (41).
Asp112 in the V1aR is conserved
throughout the neurohypophysial
hormone receptor family with the
exception of the humanV2R and the
VTR that possess Lys and Glu,
respectively. It has been reported
that this locus is important for bind-
ing some V2R-selective agonists (42).
The substitutions [D112A]V1aR,
[D112E]V1aR, and [D112K]V1aR had little effect on receptor
function; introducing Arg112, however, impaired agonist bind-
ing and signaling but had little effect on any antagonist binding.
Although Arg and Lys are superficially similar, [D112K]V1aR
and [D112R]V1aR exhibited very different affinity for AVP.
Molecular modeling revealed that Arg112 formed a stable ionic
interaction with Glu54(1.35) at the top of TMI, which was absent
with the shorter side chain of Lys112 (and also absent in wild
type and [D112E]V1aR). Glu54(1.35) has recently been identified
as a key residue for high affinity agonist binding and signaling
(15); consequently, an inappropriate interaction with Arg112
FIGURE 4.Molecular modeling of wild-type and mutant receptors. A, the overlapped positions of solvent
molecules are presented for wild-type V1aR (yellow) and [R125D]V1aR (blue) simulations. It can be seen that the
mutation [R125D]V1aR increased the solvent-accessible surface as a result of re-ordering of the phospholipids
surrounding the extracellular end of TMIII. B, themutant [D112R]V1aR enabled inappropriate hydrogen bonds
(dotted green lines) to be formed between this residue and Glu54 in TMI. C, in thewild-type V1aR, Asp
204 in ECL2
hydrogen bonds (dotted green lines) with Lys128 and Gln131 in TMIII. These contacts are broken in the mutant
[D204A]V1aR (D) which results in partial unfolding of the -hairpin structure of ECL2. E, the partially unfolded
ECL2 -hairpin structure of [D204A]V1aR (blue) is revealed when superimposed onto that of wild-type V1aR
(yellow). F, themutant [D204R]V1aR inappropriately hydrogen bonds (dotted green) with residues in TMVII and
TMII. See text for details.
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may prevent Glu54(1.35) from adopting an optimal conforma-
tion for AVP binding and signaling.
ECL2 is usually the longest ECL inGPCRs and in bRho forms
a -hairpin that projects into the binding crevice allowing the
4-strand to contact retinal (1, 2). There is also evidence that
this ECL2 fold is not restricted to bRho and occurs in other
GPCRs (43). Of the five conserved charged residues substituted
by Ala in ECL2 of the V1aR, only [D204A]V1aR had a marked
effect on receptor function, with a profound decrease in AVP
affinity, decreased LA affinity, and impaired signaling potency.
Molecular modeling revealed that Asp204 provides interactions
between ECL2 and TMIII by hydrogen bonding with
Gln131(3.32) and forming a salt bridge with Lys128(3.29). Substitu-
tion by Ala in [D204A]V1aR disrupted this contact network
resulting in partial unfolding of ECL2 and re-arrangement of
the Lys128(3.29) side chain. Substitution of Lys128(3.29) or
Gln131(3.32) byAla also disruptedAVPbinding and signaling (8),
consistent with the proposed role for Asp204. The reduction in
affinity of both AVP and LA was similar following either
removal of the negative charge ([D204A]V1aR) or charge rever-
sal ([D204R]V1aR) (Table 1). Although [D204R]V1aR and
[D204A]V1aR had the same affinity for AVP, the decrease in
potency of AVP-stimulated InsP-InsP3 production was greater
with Arg204 than with Ala204 (Table 1), suggesting that Arg204
stabilized the receptor ground state. Molecular modeling indi-
cated that for both of these constructs the interactions between
ECL2 and TMIII were disrupted in a similar manner leading to
re-organization of ECL2. However, the introduction of the lon-
ger side chain of Arg204 also created new interactions between
ECL2-TMII (Gln104(2.57) and Gln108(2.61)) and ECL2-TMVII
(Ala272(7.42) and Ser273(7.43)), which reduced the R3 R* transi-
tion. Interestingly, Ser273(7.43) corresponds to the retinal attach-
ment site in bRho, and this locus has been implicated in activa-
tion of other GPCRs (44, 45). In addition, Ala substitution of
both of theTMII contacts, Gln104(2.57) andGln108(2.61), has been
reported previously to perturb both ligand binding and intra-
cellular signaling (8). Consequently, the inappropriate new
contacts established by Arg204 are with residues required for
receptor activation and explain the perturbed pharmacological
profile observed with [D204R]V1aR. In contrast, the conserva-
tive substitution [D204E]V1aR, which occurs naturally in a
chick VTR (33), maintains the normal ECL2-TMIII contacts
and exhibits wild-type characteristics. Our investigations
establish the importance of an acidic residue at position 204
and provide an explanation for the absolute conservation of
Asp(Glu) at this locus throughout a subfamily of GPCRs. In
addition, our study also provides a feasible mechanism for the
naturally occurring “loss-of-function” mutation D191G in the
human V2R (corresponding to Asp204 in the V1aR) that has
been identified as a cause of nephrogenic diabetes insipidus
in some families (46). Asp204 is juxtaposed to the disulfide
bridge (Cys205), conserved in the majority of GPCRs, and is
therefore under positional restraint. Interestingly, the residue
corresponding to Asp204 has been reported to be functionally
important in other GPCRs. For example, Met195 of the chole-
cystokinin-A receptor is required for interactionwith cholecys-
tokinin (47), and the mutation I185A affected CXCR4 co-re-
ceptor activity for some human immunodeficiency virus strains
(48).
The functional importance of Asp204 for agonist binding and
signaling byV1aR is a property shared byArg125 (this study) and
also Arg46 in the N terminus (14). It was therefore possible that
a charge-charge interaction between Arg125-Asp204 or Arg46-
Asp204 was required for high affinity agonist binding. Interac-
tion between these two charge pairs was theoretically possible
as Arg125-Asp204 is located at opposite ends of the same disul-
fide bond, and in bRho theN terminus has been shown tomake
multiple contacts with ECL2 (1, 2). However, the double-recip-
rocal mutants [R125D/D204R]V1aR and [R46D/D204R]V1aR
were both severely compromised; therefore, our data do not
support a direct interaction of Asp204 with either Arg125 or
Arg46.
Although ECL3 charged residues are important for peptide
ligands binding to some GPCRs (49–51), substitution of the
three conserved charged residues in ECL3 of the V1aR did not
affect either ligand binding or activation of the receptor. How-
ever, the mutant [D323A]V1aR did exhibit decreased cell-sur-
face expression (50% of wild type). It is noteworthy that
Asp323 is the only ECL3 charged residue absolutely conserved
throughout the vertebrate neurohypophysial hormone recep-
tors cloned to date, suggesting that it may fulfill an important
role in maintaining cell-surface expression that is common to
all members of this family. Our data do not support the sugges-
tion (52) that ECL3 acidic residuesmight be implicated in bind-
ing AVP and vasotocin.
In conclusion, we have shown that key charged residues
located throughout the extracellular face of the V1aR are
required for normal receptor function, identifying Arg116
(ECL1), Arg125 (top of TMIII), and Asp204 (ECL2) as important
for high affinity agonist binding and/or receptor activation and
Asp323 (ECL3) as important for cell-surface expression. Con-
sistent with their fundamental role in receptor function, these
charged residues are highly conserved throughout the neuro-
hypophysial hormone receptor subfamily of GPCRs.
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